Risankizumab Anti-IL-23p19 monoclonal antibody USAN; Rec INN Treatment of psoriasis Treatment of inflammatory bowel disease Treatment of asthma

摘要

The interleukin-23 (IL-23)/T-helper 17 (Th17) axis is considered central to the pathogenesis of psoriasis, being IL-23 a critical upstream cytokine acting early in the inflammatory cascade. In addition, IL-23 and IL-23 receptor have been identified as drug targets for several other autoimmune inflammatory conditions. Risankizumab (Bl-655066) is an anti-IL-23 monoclonal antibody under development at AbbVie and Boehringer Ingelheim, designed to have greater selectivity for the p19 over the p40 subunit of the cytokine, and allowing longer dosing interval than standard biologic therapies to maintain the downregulation of immune activation. Risankizumab is currently being evaluated for the treatment of multiple inflammatory diseases, including phase ill clinical trials for moderate to severe psoriasis, Crohn's disease and ulcerative colitis; and phase it trials for psoriatic arthritis and severe persistent asthma. Safety studies displayed good tolerability without serious drug-related adverse effects. Risankizumab showed improved efficacy in comparison with ustekinumab and adalimumab, thus emerging as a meaningful new treatment option for people living with psoriasis.